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Development of glial restricted 
human neural stem cells for 
oligodendrocyte differentiation in 
vitro and in vivo
sangita Biswas1,2,3, Seung Hyuk Chung1,4, Peng Jiang1,2, Samaneh Dehghan1 & 
Wenbin Deng1,2
In this study, we have developed highly expandable neural stem cells (NSCs) from HESCs and iPSCs that 
artificially express the oligodendrocyte (OL) specific transcription factor gene Zfp488. This is enough to 
restrict them to an exclusive oligodendrocyte progenitor cell (OPC) fate during differentiation in vitro 
and in vivo. During CNS development, Zfp488 is induced during the early stages of OL generation, and 
then again during terminal differentiation of OLs. Interestingly, the human ortholog Znf488, crucial 
for OL development in human, has been recently identified to function as a dorsoventral pattering 
regulator in the ventral spinal cord for the generation of P1, P2/pMN, and P2 neural progenitor 
domains. Forced expression of Zfp488 gene in human NSCs led to the robust generation of OLs 
and suppression of neuronal and astrocyte fate in vitro and in vivo. Zfp488 expressing NSC derived 
oligodendrocytes are functional and can myelinate rat dorsal root ganglion neurons in vitro, and 
form myelin in shiverer mice brain in vivo. After transplantation near a site of demyelination, Zfp488 
expressing hNSCs migrated to the lesion and differentiated into premyelinating OLs. A certain fraction 
also homed in the subventricular zone (SVZ). Zfp488-ZsGreen1-hNSC derived OLs formed compact 
myelin in Shiverer mice brain seen under the electron microscope. Transplanted human neural stem 
cells (NSC) that have the potential to differentiate into functional oligodendrocytes in response to 
remyelinating signals can be a powerful therapeutic intervention for disorders where oligodendrocyte 
(OL) replacement is beneficial.
Adult neural stem cells (NSCs) are operationally defined as multipotent, self-renewing cells in the CNS that are 
characterized by their ability to differentiate into neurons, astrocytes, and oligodendrocytes via exogenous stim-
uli from their microenvironment1–4. They reside in the forebrain and spinal cord niches as a proliferating adult 
precursor cell population and are maintained for life5,6. NSCs have been identified as an endogenous source of 
neuroregenerative cells that are mobilized during normal adult neurogenesis as well as after acute brain and spinal 
cord injury7–9, stroke10 and after acute11 or chronic demyelination12,13. However, the modest spontaneous func-
tional recovery seen after brain injury10 indicates that endogenous NSCs have limited capacity for proliferation 
and differentiation under pathological conditions14.
A rational choice for neuro-repair, therefore, is to either transplant exogenous NSCs into the CNS with capa-
bilities to efficiently migrate to the injury site and differentiate, or to promote endogenous NSC mediated neu-
roregeneration. Transplanted NSCs may aid neuroregeneration by at least three major mechanisms. First, they 
can provide direct replacement of dead neurons or glial cells; second, undifferentiated NSCs secrete neurotrophic 
factors that directly or indirectly save the injured tissue from secondary damage; and third, they can promote 
remyelination by endogenous OLs.
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As a proof of principle, fetal human neural stem cells (hfNSCs) were tested for their capacity for OL replace-
ment and remyelination as therapeutic interventions in rodent and primate models of MS and in rodent stroke 
models. These pioneering studies have shown that hfNSCs not only survived and migrated in the inflammatory 
environment of the Experimental Autoimmune Encephalomyelitis (EAE) and ischemic brain15, they were also 
able to attenuate the clinical signs of EAE5,16,17 and ischemia-induced CNS pathology18. These studies, however, 
pointed out that grafted hfNSCs although optimally equipped for homing to the lesions were mostly neurono-
genic, and showed nominal differentiation into oligodendrocytes at the site of the lesion18,19. Thus, their beneficial 
actions were not via OL replacement. Other studies in rodents have shown that undifferentiated NSCs grafted 
into either intact or injured adult spinal cord either remain undifferentiated or differentiate to astrocytes20,21. 
Notably, these studies indicate that efficient oligodendrocyte replacement may not be achievable with naïve fetal 
NSCs, rather more lineage-restricted NSCs may be tested for developing future OL replacement strategies.
Alternate sources of NSCs are the human embryonic stem cells (hESCs) or induced pluripotent stem cells 
(iPSCs). HESC and iPSC derived NSCs have a robust capacity for self-renewal and multipotency in vitro3, and 
they have been suggested as promising candidates for cell therapy after brain injury19,22. They can successfully 
engraft after transplantation into the rodent or primate CNS, and they exhibit an innate capacity to migrate 
toward areas of CNS lesions, including ischemic, chemical, or neoplastic injury7–11. They can proliferate robustly, 
and they are amenability to viral or nonviral-mediated gene correction in vitro coupled to lack of tumorigenicity 
upon grafting where they survive, migrate, and differentiate23–25. Most importantly, transplanted NSCs can home 
in the niches, self-renew and provide a long-lasting supply of regenerative cells in vivo19,22,23. Thus, NSC transplan-
tation may be a better strategy than direct OPC transplantation.
In the mouse EAE model, transplanted hESC-derived NSCs were shown to survive and migrate26, but exhib-
ited limited oligodendrocyte differentiation, myelination or functional recovery6. Other studies found that the 
post-transplant beneficial effects in EAE were largely due to the immediate release of immune-modulatory agents 
at the site of the inflammatory lesions27,28 along with secretion of neuroprotective factors17–20 and promotion of 
endogenous OPC differentiation29. Transplantation of more fate-restricted NSCs, however, resulted in a better 
functional recovery in mouse EAE30 and SCI model compared to naïve NSCs31. Specifically, hESC derived NSCs 
differentiated to A2B5/NG2/PDGFR-α expressing OPCs have been transplanted in rat cervical SCI model and 
was found to be safe. This has initiated a phase I clinical trial for patients with thoracic SCI. Thus, it is of great 
interest to develop lineage-restricted NSCs as a source of progenitor cells capable of surviving and differentiating 
into functional OLs after transplantation into MS brain, and other conditions leading to OL death.
Thus, to generate and test human NSCs that are mainly committed to an oligodendroglial fate, we have devel-
oped hESCs and iPSCs derived hNSCs that constitutively express the transcription factor Zfp488. Zfp488 is a 
key regulator for the development of oligodendrocyte lineage cells and differentiation of OPCs32,33. Originally 
it was thought to be exclusively expressed in differentiating OL32,33. However, results from an RNA-sequencing 
transcriptome and data base of cells in the cerebral cortex show that Zfp488 gene is expressed in the newly formed 
oligodendrocytes and plays a crucial role in their terminal maturation34. A previous study from our laboratory 
showed that when adult mouse subventricular zone (SVZ) NSCs were transduced in vivo by injecting Zfp488 
gene carrying retroviral particles (with ZsGreen1 reporter), they differentiated primarily into OPCs following 
cuprizone-induced demyelination32. Misexpression of Zfp488 in SVZ NSPCs significantly increased the number 
of mature ZsGreen1 positive OLs in the corpus callosum which translated to functional recovery of motor func-
tion deficit these mice32. This indicated that Zfp488 expression selectively directed the fate of mouse endogenous 
NSCs towards generating functional OL in vivo.
In the current study, we have tested the differentiation potential of hESCs and iPSC derived 
Zfp488-ZsGreen1-hNSCs compared to control hNSCs in vitro as well as in vivo in a mouse model of demy-
elination. We demonstrate that forced expression of Zfp488 in human NSCs directs them towards an OPC 
fate while largely suppressing astrocytes or neuronal fate. This OPCs can efficiently mature into OLs in vivo 
after transplantation in mouse LPC induced corpus callosum demyelination model. We also demonstrate that 
Zfp488-ZsGreen1-hNSCs can myelinate the shiverer mouse brain after transplantation and myelinate rat dorsal 
root ganglion (DRG) neurons in vitro. In contrast, control hNSCs largely remain undifferentiated in vivo (with 
some astrocyte differentiation) within the same time frame.
Methods
Generation of NSCs from hESCs and iPSC. hESC lines (H9 and BG01) and iPSCs (foreskin, clone 3)35–37 
were a kind gift from Dr. James Thomson (University of Wisconsin-Madison, Madison, WI). IPSCs were gen-
erated in Thomson lab from human newborn foreskin fibroblasts (ATCC, USA) transduced with Oct4, SOX2, 
NANOG, and LIN28 containing lentiviruses. This resulted in constitutive expression of the transgenes. Cells were 
grown under feeder-free and serum-free conditions on hESC qualified Matrigel 4 mg/ml (Becton Dickinson, 
USA) coated plates in mTeSR1 media (Stemcell Technologies, USA). hNSCs were derived according to the pro-
tocol provided by the manufacturers (Thermo Fisher Scientific, USA). Briefly, on day 0 of splitting (15–20% con-
fluency) (Fig. 1A), PSC Neural Induction Medium (Thermo Fisher Scientific, USA) was added into each well of 
6-well plate of cells. Media was completely replaced on day 2, 4 and 6. On day 7 of neural induction cells are 90% 
confluent (Fig. 1B). Cells were passaged every 48–72 hours and expanded with neural expansion media (Thermo 
Fisher Scientific, USA). At passage 4–5, a population of NSCs with homogeneous morphology was obtained 
(Fig. 1G). These cells were either stocked or used for differentiation (population doubling time 48 hours).
Characterization of hNSCs. Immunocytochemical staining and RT-PCR was used to determine the phe-
notypes of the NSCs. hNSCs plated on Matrigel-coated chamber slides were fixed with 4% paraformaldehyde/
PBS and immunostained with NSC markers nestin, SOX2, PAX6, and pluripotency marker Oct4, using stand-
ard immunocytochemistry techniques. After washing with PBS, cells were permeabilized for 10 minutes in 0.1% 
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Triton X-100 and incubated for 1 hour in blocking buffer (5% goat serum and 1% bovine serum albumin in PBS). 
Cells were then incubated overnight at 4 °C in primary antibodies diluted in blocking buffer (see Table 1 in sup-
plementary document 1 for antibody dilutions and sources). Appropriate fluorescence-conjugated secondary 
antibodies (Alexa Fluor, Invitrogen, USA, dilution 1:1000) were used for single or double immunostaining.
Generation of Zfp488-ZsGreen1-hNSCs and control ZsGreen1-hNSCs. Zfp488 and control len-
tiviral particles (both containing the ZsGreen1 reporter gene) used in this study were previously generated 
and tested for gene expression in our laboratory32. The mouse Zfp488 cDNA was a kind gift from Dr. Richard 
Lu (University of Texas Southwestern Medical Center, Dallas, TX, USA). The Zfp488 open reading frame was 
cloned into the pRetroX-IRES-ZsGreen1 vector (Clontech Laboratories, Mountain View, CA).The empty 
pRetroX-IRES vector expressing ZsGreen1 was used as a control. Retroviral particles were produced from 
pRetroX-Zfp488-IRES-ZsGreen1 and pRetroX-IRES-ZsGreen1 (control) at the Gene Transfer Vector Core, 
University of Iowa (Iowa City, IA). Titers for the concentrated stocks were obtained for both the viruses and were 
2 × 108 transducing units/ml. The Zfp488 gene is conserved between human and mouse (NCBI BLAST search). 
There is 56% homology in the amino acid sequence between the mouse and human Zfp488 protein and the zinc 
finger domains are conserved.
Passage 5 (P5) NSCs were infected with either Zfp488 or control retroviral vectors. NSCs were plated on 
Matrigel (4 mg/ml, Corning, USA) coated 6 well plates (0.3 × 106 cells in each well). Zfp488 or control lentivi-
ral particles (50 μl virus in 1 ml neural expansion media per well) and polybrene 6 μg/mL were added to each 
well. Plates were then sealed with parafilm and spun at 500 g for 30 min at 32 °C for increasing the efficiency of 
infection, followed by incubation in a CO2 incubator for 12–16 hours. Next day, the virus-containing media was 
discarded, and fresh neural expansion media was added. Cells were then allowed to recover for 4 hours, after 
which the second round of infection was performed for 6 hours using the same protocol. After infection cells were 
washed twice with PBS and cultured in neural expansion media until they were 90% confluent. Cells were split 
1:3 in Matrigel-coated 6 well plates in neural expansion media for expansion. NSCs (P5-6) stocked at this stage in 
liquid nitrogen were successfully recovered for future use.
Figure 1. Adherent hESC–H9 colonies (A) treated with neural induction media for 7 days generated neural 
tube-like structures (B). After 7 days, cells were cultured as neurospheres in ultralow attachment plates (C). (D–
H) Immunohistochemical analysis of hESC derived hNSCs. Passage 3 putative NSCs expressed neural stem cell 
markers SOX2, Pax6 and nestin (D,E,H respectively). Passage 5 (P5) hNSC represented cells with homogenous 
NSC morphology, and more than 97% of cells expressed nestin. These results were also confirmed by RT-PCR 
(I). Retrovirus transduction was confirmed by expression of ZsGreen1 fluorescence following differentiation of 
NSCs (J,K respectively).
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Differentiation of control and Zfp488-ZsGreen1-hNSCs. Zfp488-ZsGreen1-hNSCs (P5-6) were 
evaluated for their potentials to differentiate into neurons or glial progenitor cells in vitro. Two different proto-
cols, spontaneous as well as directed differentiation were used. Uninfected hNSCs, as well as hNSCs expressing 
only ZsGreen1 reporter (control hNSCs), were used as positive controls which could differentiate into neu-
rons and astrocytes. For spontaneous differentiation, dissociated hNSCs were plated onto laminin (10 μg/ml, 
Sigma-Aldrich, USA) coated chamber slides at a density of 6.0 × 104 cells per cm2. They were cultured under 
differentiation conditions (neurobasal media, 1x B27 supplement, and glutamax 2 mM) for 2–3 weeks without 
any growth factors.
For astroglial differentiation, dissociated NSCs were plated onto poly L-ornithine and laminin double-coated 
chamber slides at a density of 5.0 × 104 cells per cm2 in an astrocyte differentiation medium (DMEM supple-
mented with 1% N2 supplement and 5% fetal bovine serum, Invitrogen USA) for 3 weeks to 7 weeks. Confluent 
cultures were passaged, and the medium was refreshed every 3–4 days. Differentiated cells were characterized 
by S100 beta at 3 weeks and GFAP immunostaining at 6 weeks (see supplementary document 1, figure B for the 
precise timeline of differentiation).
For directed OPC generation, dissociated Zfp488-ZsGreen1-hNSCs (P5-7) were plated onto poly-L-ornithine 
and laminin-coated coverslips at a density of 5.0 × 104 cells per cm2 in OPC media 1 (DMEM/F12 medium, N2 
supplement, 10 ng/ml basic fibroblast growth factor-2 (bFGF-2), 20 ng/ml epidermal growth factor (EGF) and 
1 µM retinoic acid). After 1 week the cells were grown in OPC media 2 (DMEM/F12, 1% N2 supplement, 2% B27 
supplement, 10 ng/ml PDGF-AA, insulin-like growth factor 10 ng/ml, NT3 10 ng/ml, and the sonic hedgehog 
agonist pumorphamine 1.0 µM, T3 30 ng/ml, biotin 100 ng/ml, and cAMP 1μM) for an additional 6–7 weeks. The 
early glial restricted precursor was assessed by A2B5 in some cases, and then by OPC markers PDGFR-α, NG2, 
Sox10, and Olig2 which were expressed between 3–4 weeks and used to characterize and quantify the cells. Half 
of the media was changed every other day throughout the protocol (see figure B in supplementary documents 1 
for the timeline of OPC differentiation and characterization).
Differentiation of FACS purified ZsGreen1/Zfp488+ OPCs. FAC sorted ZsGreen1 positive OPCs 
grown in suspension cultures were plated on Poly-L-ornithine and laminin-coated coverslips in OPC media 2 
(DMEM/F12, N2 supplement100x, B27 supplement 50x, PDGF-AA 10 ng/mL, insulin-like growth factor 10 ng/
ml, NT3 10 ng/ml, the sonic hedgehog (SHH) agonist pumorphamine 1.0 µM, T3 30 ng/ml, biotin 100 ng/ml, and 
cAMP 1μM). Media was changed every other day. After 5 weeks, the immunofluorescence study was performed 
on these cells to find the percentage of late OPCs by expression of O4 marker. Next, cells were differentiated in 
OL media (DMEM/F12, N2 supplement 100x, B27 supplement 50x, T3 30 ng/ml and ascorbic acid 20 mg/mL) 
only for one week. Then, immunofluorescence assay was performed on these cells to find the percentage of pre-
myelinating oligodendrocytes by the expression of O1 and MBP (see figure B in supplementary documents for 
the timeline for differentiation).
In vivo differentiation of Zfp488-ZsGreen1-hNSCs and control hNSCs after transplantation 
in a model of focal demyelination in mice. We compared the abilities of Zfp488-ZsGreen1-hNSCs 
and control hNSCs to engraft and differentiate in vivo following transplantation in a focal model of demyeli-
nation induced by a single injection of lysolecithin (LPC) in the corpus callosum of adult Rag-2 knockout mice 
(B6(Cg)-Rag2tm1.1Cgn/J, Jackson Laboratories, USA)38. Details of mice surgery are in supplemental document 
1. In this model, demyelination occurs in about 48 hours and reaches maximum levels in 3–5 days12.
ZsGreen1 fluorescence and human nestin antibody were used to track the grafted cells. Double labeling 
immunofluorescence staining using antibodies against lineage-specific markers were used to compare the fate 
of Zfp488-ZsGreen1-hNSC and control ZsGreen1-NSCs (details of the antibodies are provided as Table 1 in 
supplementary documents). All animal procedures were approved by the IACUC committee of the University of 
California Davis. All experiments (in vitro and invivo including supplementary information) were performed in 
accordance with relevant guidelines and regulations.
Myelination of shiverer mice brain by Zfp488-ZsGreen1-hNSCs. Shiverer mice (C3Fe.
SWV-Mbpshi/J, The Jackson Laboratory, USA) lack myelin basic protein and myelin in the CNS39,40. Shiverer mice 
8–10 weeks old (N = 3, each group) were anesthetized and injected with 50,000 iPSC derived Zfp488-ZsGreen1/
PDGFR-α+ OPCs or sham injected with the same volume of phosphate buffered saline into the corpus callosum 
(surgical procedure and stereotaxic coordinates were identical with the LPC injections coordinates). Mice were 
administered cyclosporine 10 mg/kg, intraperitoneally daily for 8 weeks for immune suppression after which 
they were sacrificed. Brains were processed for electron microscope imaging. One-micron meter sections of the 
injected areas were analyzed for the formation of the multilayered compact myelin sheath. We could not derive 
enough control OPCs (with the empty virus) for transplantation using this protocol. All animal procedures were 
approved by the IACUC committee of UC Davis. All experiments (in vitro and invivo including supplementary 
information) were performed in accordance with relevant guidelines and regulations.
Myelination of rat dorsal root ganglion (DRG) neurons by H9 derived Zfp488-ZsGreen1- 
hNSCs. Rat DRG (Lonza Inc, USA) were plated on collagen type I-coated coverslips (2–3 ganglion per coverslip) 
and allowed to mature for two weeks in primary neuronal growth media (Lonza Inc, USA). Non-neuronal cells (rat 
OPCs) were eliminated by cycling them three times with medium containing 5-fluorodeoxyuridine 0.1 μM and uri-
dine 0.1 μM. Zfp488-ZsGreen1-iPSCs derived NSCs were differentiated to O4 expressing late OPCs. O4+ cells were 
identified by live immunostaining. O4 positive OPCs were then plated on top of the DRG neurons and cultured for 
three weeks in OL myelination medium (see supplementary document 1). After three to four weeks cells were fixed 
and immunostained for SMI312 (for neurofilament), myelin basic protein (MBP) or proteolipid peptide (PLP) for 
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myelin and imaged by a confocal microscope (Nikon C1, USA). All experiments (including supplementary informa-
tion) were performed in accordance with relevant guidelines and regulations set by UC Davis.
Sox9 RT-PCR. Semiquantitative assay of Sox9 mRNA levels were done on Zfp488-ZsGreen1-hNSCs and 
control ZsGreen1-hNSCs immediately before differentiation, and after 3 days of differentiation in OPC media 
using the TaqMan gene expression system (N = 3 for each group). Presence of Sox9 protein was confirmed by 
immunohistochemistry using anti sox9 antibody (catalog # AF3075, R&D Systems, USA, N = 3, for each group).
Statistical analysis. The differences in the numbers of Zfp488-ZsGreen1-hNSCs and control 
ZsGreen1-hNSCs that double labeled for OPC and astrocyte markers were compared by Students t-test. RT-PCR 
data were analyzed by one-way ANOVA followed by Students t-test.
Results
hNSCs derived from hESCs without embryoid body formation expressed neural stem cell mark-
ers. H9 hESC colonies (Fig. 1A) when exposed to neural induction media for 7 days changed morphology with 
the appearance of neuro rosette-like structures (Fig. 1B). After 1 week of neural induction, the putative P0-P1 
NSCs expanded proficiently as monolayers in neural expansion media. hNSCs at P2-P5 were expanded as neuros-
pheres in suspension culture (Fig. 1C). Neurospheres were then dissociated and expanded as adherent monolayer 
cultures. Putative hNSCs between passage 3–5 were immunostained for expression of NSC markers Sox2, nestin, 
Pax6 (Fig. 1D–F) and pluripotency marker Oct4. At P3, cells (<95%) were positive for Sox2 (Fig. 1D), PAX6 
(<60%) (Fig. 1E), and nestin (~50%) (Fig. 1F). At P5 the plated cells showed homogeneous NSC morphology 
(Fig. 1G), and almost all cells expressed nestin (<97%) (Fig. 1H). Oct4+ cells were rarely seen (2.5 ± 0.6%). We 
confirmed the expression of sox2, pax6 and nestin in P5 hNSCs at the mRNA level by RT-PCR (See supplemen-
tary document Fig. A for iPSC and BG01 NSC data). The amplicon product sizes were as follows; nestin 81 bp, 
sox2 91 bp, pax6 86 bp, and GAPDH 157 bp (iPSC and BG01 derived P5-NSC data is included in supplementary 
document Table 2). Data for the characterization of iPSC derived NSCs are shown in supplementary document 
1. Under our defined growth conditions, the hNSCs showed stable growth. The cells were highly proliferative in 
the presence of EGF and bFGF, and we speculate that billions of hNSCs could be produced over a period of 3–4 
months. We expanded the isolated hNSCs cells for over 15 passages. Normally NSC generation by this protocol 
generates less than 5% OPCs in vitro. Their major fate is to differentiate into neuron (70–90%), and astrocytes 
(20–35%).
Generation of Zfp488-ZsGreen1-hNSCs and control-hNSCs. A well-characterized repressor ele-
ment present in stem cells prevents the expression of the Moloney Leukemia Retroviral -Long Terminal Repeat 
(MoMuLV-LTR) promoter prior to their differentiation into somatic or progenitor cells41. This unique property 
allowed us to “switch on” Zfp488 expression as the neural stem cells start to differentiate, but not during their 
self-renewal and expansion. Accordingly, after infecting the hNSCs, we confirmed that there was no expression 
of ZsGreen1 prior to the beginning of differentiation. Aliquots from the infected hNSCs were then differentiated 
by culturing them in DMEM/F12 with N2 and B27 supplements (without bFGF or EGF) to assess the efficiency 
Figure 2. Astrocyte differentiation of control and Zfp488-ZsGreen1-hNSCs. (A) In Zfp488 group a low 
fraction of ZsGreen1+ cells expressed S100-beta (6.8 ± 3.5%) after 3 weeks of culture in astrocyte differentiation 
medium. (B) In contrast, half of (53.5 ± 7.2%) of ZsGreen1+ control hNSCs expressed S100-beta (see 
arrowheads). (C) Confocal image quantification of cells that co-labeled for ZsGreen1 and S100beta in the 
two groups showed that significantly higher number of the control hNSCs differentiated into S100-beta+ cells 
(Students unpaired t-test, P < 0.001). After 6 weeks of differentiation, GFAP+ astrocytes were detected in 
both groups (D,E). (E) Zfp488-ZsGreen1-hNSC had nominal GFAP expressing cells (10.6 ± 1.4%), whereas a 
significantly larger fraction of control ZsGreen1-hNSCs expressed GFAP (36.8 ± 7.4%, P < 0.0001) (D). Thus, 
Zfp488 expression largely prevented an astrocyte fate after differentiation. Scale-50 μM.
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of infection by counting the number of ZsGreen1 positive cells. These viruses were from the same batch that 
was previously generated and characterized in our laboratory32. Expression of Zfp488 was earlier confirmed and 
reported after a trial retroviral infection in 293T cells using both ZsGreen1 reporter fluorescence and western 
blots32. Transfection efficiency was assessed by differentiating aliquots of H9-derived control ZsGreen1-hNSCs 
or Zfp488-ZsGreen1-hNSCs spontaneously (by withdrawing growth factors EGF and bFGF from the media) 
to allow for ZsGreen1 expression. The number of ZsGreen1+ cells were found to be ~85% for control groups 
(Fig. 1J), and ~7% for the Zfp488 group. However, when Zfp488 infected cells were differentiated in OPC media 
for 3 weeks 70–80% cells became ZsGreen1 positive (Fig. 1K). Aliquots from these batches were frozen and recov-
ered later for OPC differentiation and FAC sorting (via ZsGreen1 fluorescence) for in vivo transplantation studies 
in LPC-demyelination model in mouse. Zfp488-hNSCs were successfully derived from hiPSCs and BG01 hESC 
cells (Supplementary Figs 4 and 5 respectively).
ZFP488 misexpression suppressed astrocytic fate in vitro. After culturing the H9 derived NSCs for 
three weeks in OPC differentiation medium, 53.5 ± 7.2% of control ZsGreen1-hNSCs expressed the astrocyte 
marker S100 beta (Fig. 2B). In contrast, a significantly lower fraction of Zfp488-ZsGreen1-hNSCs expressed 
S100 beta (6.8 ± 3.5%, P < 0.001) (Fig. 2A). Cells were further allowed to differentiate up to 6 weeks to allow for 
GFAP expression. A lower fraction (10.6 ± 1.4%) of Zfp488-ZsGreen1-hNSC expressed GFAP (Fig. 2E), while 
Figure 3. For directed OPC differentiation the Zfp488-ZsGreen1-hNSCs were plated as a monolayer on 
laminin-coated plates. In Zfp488 group, after 4–5 weeks of differentiation 74.0 ± 3.0% of ZsGreen1 positive 
cells were NG2+ (A-A2), 83.8 ± 3.8% cells were sox10+ (B-B2), 93.2 ± 1.2%, Olig2+ (C-C2) and 87.0 ± 4.2% 
PDGFR-alpha+ (D-D2). The bar graph shows the percentages of green cells that express different markers (J). 
We could not derive quantifiable cells expressing OPC markers from control hNSCs using this protocol. Next, 
the H9-derived Zfp488 NSCs were FAC sorted using ZsGreen1 fluorescence reporter using FITC-A channel on 
Aria II FACS (E). The sorted cells formed spheres after overnight culture in ultralow attachment plates (F) and 
could be easily expanded in neural expansion media and formed a monolayer after plating on laminin-coated 
plates (G). FACS sorted ZsGreen1-OPCs, were induced to further differentiation. The percentage of Zfp488 
cells expressing O4 was 68.7 ± 4.2% at day 14 after differentiation with thyroid hormone and morphologically 
resembled mature oligodendrocytes (H-H2). Further differentiation for at least 1 more week resulted in 
approximately 59.5 ± 3.7% of ZsGreen1+/O1+ cells (I-I2).
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a significantly large fraction (36.8 ± 7.4%, P < 0.0001compared to Zfp488 group) of control ZsGreen1-hNSC 
expressed GFAP (Fig. 2D). Bar graph (Fig. 2C) shows the percentages of S100beta+/ZsGreen1+ and GFAP+/
ZsGreen1+ cells. Thus, Zfp488 expression largely created an oligodendrocyte lineage bias during differentiation 
of the hNSCs.
ZFP488 misexpression increases the yield of hNSC–derived OPCs, and mature oligodendrocyte 
in vitro. The percentages of ZsGreen1 cells expressing stage-specific OPC markers were evaluated by immu-
nohistochemistry (Fig. 3). The cells that co-labeled for ZsGreen1 and various OPC markers were counted and 
expressed as a percentage of total ZsGreen1+ cells. In Zfp488 group, after 4–5 weeks of differentiation 74.0 ± 3.0% 
of ZsGreen1 cells were NG2+ (Fig. 3A), 83.8 + 3.8% cells were sox10+ (Fig. 3B), 93.2 + 1.2% were Olig2+ (Fig. 3C) 
and 87.0 + 4.2% were PDGFR-α+ (Fig. 3D). The bar graph shows the percentages of green cells that express 
different markers (Fig. 3J). We could not derive quantifiable cells expressing OPC markers from control hNSCs 
using this protocol (less than 5% NG2 positive cells were seen after 4 weeks but they could not survive for more 
than a week).
Next, the H9-derived Zfp488 NSCs were FAC sorted using ZsGreen1 fluorescence (BD FACsAria II and BD 
FACSDiva software, USA) (Fig. 3E). The sorted cells formed spheres after overnight culture in ultralow attach-
ment plates and could be easily expanded in neural expansion media (Fig. 3F). After plating the spheres, cells 
formed a monolayer within a few days with a mean doubling time of 48 hours (Fig. 3G). Since Zfp488 is a critical 
TF expressed during differentiation of OPCs during development, we took FACS sorted ZsGreen1+/OPCs and 
induced them to further differentiate. The percentage of Zfp488+ cells expressing the pre-OL marker O4 was 
68.7 ± 4.2% at day 14 after differentiation with thyroid hormone (Fig. 3H). Further differentiation for at least 
1 additional week resulted in approximately 59.5 ± 3.7% of ZsGreen1+ were O1+ (Fig. 3I). We detected a few 
ZsGreen1 positive astrocytes (not shown). Therefore, Zfp488 misexpression allowed the terminal differentia-
tion to mature OLs after directed invitro differentiation. Thus, ZFP488 expression alone was enough to induce 
expression of markers of the OPC/oligodendrocyte lineage in differentiating NSC that were generated without 
dorso-ventral patterning of EB with morphogens.
Expression of Zfp488 during spontaneous differentiation of H9 derived hNSCs prevented their 
default neuronal fate in vitro. Following 3 weeks of spontaneous differentiation of monolayer cultures, 
majority of the untransduced (supplementary documents Fig. 1A) and control ZsGreen1-hNSCs (green cells, 
Supplementary Fig. 1B) differentiated into beta III tubulin positive immature neurons. In contrast, Zfp488+/
ZsGreen1+ hNSCs cells rarely differentiated into beta-tubulin positive neurons (Supplementary Fig. 1C). Thus, 
expression of Zfp488 prevented the hNSC from acquiring their default fate of differentiating into neurons after 
removal of growth factors. Similar results were obtained from Zfp488 expressing neurospheres (Supplementary 
Fig. 2).
Migration of transplanted H9 hESC derived Zfp488-ZsGreen1-hNSCs and control-NSCs in 
a model of focal demyelination model. We assessed the fate of zf488-ZsGreen1-hNSCs in vivo in a 
context-dependent manner by transplanting them near the site of an acute demyelinating lesion in the corpus cal-
losum (Fig. 4A–C). Control ZsGreen1-hNSCs (carrying only the reporter) were also transplanted under the same 
experimental conditions in different mice. A single injection of lysolecithin in the corpus callosum of adult mice 
resulted in focal demyelination within 48–72 hours (arrows, Fig. 4D,G) that typically elicits a repair response lead-
ing to spontaneous remyelination beginning within 3–4 weeks. This provided an environment where host-derived 
Figure 4. Transplantation of Zfp488-ZsGreen1-hNSCs and control ZsGreen1-hNSCs in the corpus callosum 
(CC) of mice near a demyelinating lesion for in vivo differentiation. (A) Schematic diagram of the NSC injection 
site and lysolecithin injection site in the CC. Transplanted (ZsGreen1 reporter) cells in both groups were mainly 
distributed along the corpus callosum (low power image, B,C). A single dose of lysolecithin resulted in focal 
demyelination at the injection site as indicated by a loss in MBP staining (D,G). Both Zfp488-ZsGreen1-hNSCs 
and control ZsGreen1-hNSCs migrated towards the lesion site (E,H respectively). The transplanted human 
NSCs were also identified by an antibody specifically against human nestin (F,I). A small fraction of human 
nestin-positive cells were detected in the SVZ from both groups, indicating possible homing of hNSCs (F1-F2). 
The scale is 50 μM.
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cues required for NSC migration and differentiation, and OPC maturation were present immediately after 
transplantation.
A fraction of Zfp488-ZsGreen1-hNSCs and control hNSCs were engrafted as detected by ZsGreen1 reporter 
positive cells (at or near the injection site) and survived for at least 4 weeks (Fig. 4B,C). Both hNSCs migrated 
along the corpus callosum towards the lesion site and populated the area in and around it (Fig. 4E,H). NSCs 
were also detected by human-specific nestin antibody. Human nestin+ NSCs were found mostly concentrated 
at the lesion site in the corpus callosum (Fig. 4F,I). Although the injection site was far from SVZ, the presence of 
exogenous NSC was detected with human nestin antibody in SVZ in both groups (Fig. 4F1-2). Since the NSCs 
remained undifferentiated hence no ZsGreen1 fluorescence was detected.
Transplanted Zfp488-hNSC differentiates efficiently into OPCs and OLs than control hNSC under a 
demyelinating condition. Immunofluorescence staining using antibodies against OPC lineage markers 
showed that 69.4 ± 3.0% of ZsGreen1+ cell in Zfp488-ZsGreen1-hNSCs coexpressed PDGFR-α (Fig. 5A-A2,C) 
compared to 20.0 ± 4.7% (P < 0.01) in control group (Fig. 5B-B2,C). The PDGFR-α+ OPCs were also of more 
mature morphology than the control group as evident by their long processes (Fig. 5A1). We found that 
10.0 ± 0.8% of ZsGreen1+/Zfp488-ZsGreen1-hNSCs cells coexpressed the GALC, a marker for mature oligoden-
drocytes (Fig. 5D-D2). We did not detect ZsGreen1/GALC positive cells in the control hNSC group (not shown). 
Figure 5. Comparison of in vivo differentiation of Zfp488-ZsGreen1-hNSCs and control-hNSCs into PDGFR-
alpha positive OPCs within the lesion in the CC (A,B respectively). In Zfp488 group, 69.4 ± 3.0% of ZsGreen1 
cells coexpressed PDGFR-α (see arrows in A2). The PDGFR-α+ OPCs exhibited a relatively more mature 
morphology than the control group as evident by their extended processes. In contrast, 20 ± 4.7% of the control-
hNSCs were found to differentiate into PDGFR-α expressing OPCs as shown by co-labeling of PDGR-α and 
ZsGreen1 (B-B2). (C) Quantification of PDGFR-α immunohistochemistry. A few ZsGreen1+/GALC+ double 
labeled were also seen in the Zfp488-ZsGreen1-hNSC group (5D-D2). Confocal images of neurofilament 
immunostaining (with SM312 antibody) showed that ZsGreen1+ tracts coaligned with the neurofilament tracts 
in Zfp488-ZsGreen1-hNSC transplanted brains (E-E2). Inset (E2) shows the wrapping of ZsGreen1 positive 
sheath around a section of SMI312+ axon. No co-labeling was seen with control hNSCs (F-F2). Within the 
lesion, in the Zfp488 group, ZsGreen1+/MBP+/nestin− cells were detected (G-G1, arrows). In contrast, in 
control NSC group, many ZsGreen1 cells were nestin positive indicating that they did not differentiate (H-H1). 
Blue nuclei, Hoechst staining. Bar (for all panels) is equal to 100 μM. Abbreviations: CC, corpus callosum; 
GFAP, glial fibrillary acidic protein; ZsGreen1, Zoanthus sp green fluorescent protein.
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In the Zfp488 group, we detected ZsGreen1+ tracks overlapped with the SMI312+ axonal tracts (Fig. 5E-E2). 
We did not detect similar tracks in the control group (Fig. 5F-F2). In the Zfp488 group, we also detected a few 
ZsGreen1+ cells expressing MBP, and nestin was not expressed by any green cells. In contrast, in the control 
group, many ZsGreen1 cells still expressed nestin indicating that they remained immature (Fig. 5G-G1,H-H1 
respectively). We also did not detect any ZsGreen1+ cells expressing neuronal marker Tuji in any group (not 
shown). Thus, Zfp488-ZsGreen1-hNSCs predominantly differentiated into oligodendrocyte lineage cells within 
4 weeks in vivo.
Transplanted Zfp488-hNSC rarely differentiated into astrocytes at the lesion site. 9.8 ± 2.6% 
of Zfp488-ZsGreen1-hNSCs co-labeled with GFAP at the lesion site indicating a low potential for differentiation 
into astrocytes (Fig. 6A,B,B2). In contrast, 42.0 ± 2.2% of Zsgreen+ control-hNSCs showed astroglial differenti-
ation predominantly in the lesion area as evidenced by significantly greater (P < 0.001) co-labeling of ZsGreen1 
and GFAP signals (analyzed using a confocal microscope) (Fig. 6D,C-C2). In both groups of mice, endogenous 
astrogliosis was evidenced by the presence of GFAP+/ZsGreen1− cells seen at the lesion site. The bar graph shows 
quantification of immunohistochemistry data.
Zfp488-OLs can myelinate rat dorsal root ganglion neurons in vitro co-cultures. Zfp488-ZsGree
n1-hNSCs derived O4 expressing OLs were plated on top of the 15 days old DRG neurons (Lonza, USA) and 
were co-cultured for three weeks in OL myelination medium (see supplementary document 1 for information on 
media). By two weeks of co-culture, extensions of Zfp488-ZsGreen1-OLs (identified by green cell body and pro-
cesses) aligned with the pan axonal marker SMI312+ axons at multiple locations (Fig. 7A-A2). Confocal images 
show the presence of ZsGreen1+ (green) sheaths wrapped around more than one axon (Fig. 7A1). By 3 more 
weeks, large segments of SMI312+ axons (green) were wrapped by with MBP and PLP positive myelin sheath 
(Fig. 7B-B2). ZsGreen1 expression was extremely low at this point in the Zfp488 oligodendrocytes.
Human iPSCs derived Zfp488-NSCs differentiated into OPCs that generated functional OLs 
that formed multilayered myelin in myelin deficient shiverer mouse brain. To demonstrate the 
robustness of the protocol, we also generated Zfp488-NSCs derived OLs from a human iPSCs. The percentages 
of ZsGreen1 cells that were A2B5+ (after three weeks in OPC 2 media) was 80.5 ± 2.7% (Fig. 8A-A2). After four 
Figure 6. Comparison of in vivo differentiation of Zfp488-ZsGreen1-hNSCs and control-hNSCs into astrocytes 
within the demyelinating lesion in the CC using GFAP antibody (A,D, low power). Co-labeled GFAP+ (red) 
(B1), and ZsGreen1+ cells (B2) revealed that only a few double-labeled cells (B, arrows) among the transplanted 
surviving Zfp488-ZsGreen1-hNSCs had differentiated into an astrocytic cell lineage. In contrast, numerous 
transplanted control ZsGreen1-hNSCs were found to differentiate into GFAP+ astrocytes (red, fig. C, arrows), 
as shown by co-labeling of GFAP (red, C1), and ZsGreen1 reporter (C2). Quantitative analysis of the confocal 
images showed that 9.8 ± 2.6% in Zfp488-hNSCs differentiated into GFAP astrocytes while 42.0 ± 2.2% in 
control-hNSCs differentiated into GFAP+ astrocytes (see bar graph). Blue nuclei, Hoechst staining. Bar (for all 
panels) is equal to 100 μM. Abbreviations: CC, corpus callosum; GFAP, glial fibrillary acidic protein; ZsGreen1, 
Zoanthus sp green fluorescent protein.
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weeks of differentiation, the percentage of ZsGreen1 cells that were PDGFR-α+ was 80.5 ± 2.7% (Supplementary 
Fig. 4). The percentage of O4+ cells was 64.8 ± 2.8% after 7–8 weeks of differentiation (Fig. 8B-B2), and 
55.8 ± 2.9% were O1+ (Fig. 8D-D2). Control NSCs primarily differentiated into Tuji positive neurons (~78%), 
S100-beta+ astrocytes (~27%), and few O4+ cells which did not divide (~8%)(Supplementary Fig. 5). To demon-
strate that Zfp488-ZsGreen1-hNSC derived OLs can form multilayered myelin, we transplanted O4+ cells in the 
corpus callosum of adult shiverer mouse (N = 3). Mice were sacrificed after 8 weeks and the brain was processed 
for EM. Zfp488 expressing OLs successfully myelinated the axons in shiverer mice. Multilayered compact myelin 
sheath was seen around several axons (Fig. 8E-E1). We did not detect multilayered compact myelin in the corpus 
callosum of control un-transplanted shiverer mice (Fig. 8F).
Discussion
A key prerequisite for the biomedical applications of human NSCs for oligodendrocyte replacement is their 
controlled differentiation into oligodendrocyte lineages cells in vivo. The zinc-finger protein Zfp488 is an 
oligodendrocyte-specific critical transcriptional co-regulator. It is expressed in newly formed OLs and again dur-
ing terminal differentiation of OL in rodents and human. Specifically, Zfp488 physically interacts with another 
OL lineage-specific transcription factor Olig2 to promote oligodendroctye differentiation33. In this study, we show 
that forced expression of Zfp488 in human NSCs (hESC or iPSC derived) during their differentiation directs them 
predominantly towards an oligodendrocyte fate both in vitro and in vivo. For comparing the oligodendrocyte fate 
of the transplanted NSCs in vivo, we chose a limited time frame of four weeks since majority of control-hNSCs 
remain undifferentiated or differentiate into astrocytes during that time42. We found that within four weeks of 
transplantation into the mouse corpus callosum the majority of Zfp488 expressing hNSCs appeared to have dif-
ferentiated into OPCs or premyelinating oligodendrocytes (with nominal astrocyte differentiation).
Interestingly, both rodent and human NSCs generally show a clear bias toward differentiation into astro-
glia in vivo42,43. Specifically, hESC derived hNSCs primarily give rise to astrocytes (35–60%) and nominal oligo-
dendrocytes (2–5%) in vitro44–46 and also after transplantation in the demyelinating models. However, primary 
human NSCs artificially overexpressing the olig2 transcription factor gene can differentiate predominantly into 
myelinating oligodendrocytes and contribute to the remyelination of the corpus callosum as well as promote 
locomotor recovery30. Overexpression of Olig2 has been reported to be associated with specific aspects Down 
Figure 7. Zfp488-ZsGreen1-hNSC derived OLs can myelinate rat dorsal root ganglion neurons (DRG) in vitro 
(A-A2 and B-B2). Confocal images of the co-culture between rat DRG neurons and iPSC derived Zfp488-
ZsGreen1-OLs showing multiple ZsGreen1+ OLs in contact with SMI312+ (red) axons. The co-labeled areas 
appear yellow. (A1,A2) Magnification of a representative region with a mature OL extending its processes over 
axons stained with SMI312 (red, A2). The co-labeled areas appear yellow. (B) Sections of SMI312+ (green) 
axons were wrapped with MBP+ (red, B1) and PLP+ (magenta, B2) myelin sheath. Scale bars: 10 μM (A-A2), 50 
μM (B-B2) 10 μM.
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syndrome pathology in the brain, therefore the significance of olig2 overexpression in NSC remains to be studied. 
Our focus was on Zfp488 since studies from our own laboratory have shown that mouse SVZ NSCs when trans-
duced in situ with Zfp488-retrovirus, specifically adopted an oligodendrocyte fate after differentiation following 
cuprizone-induced demyelination32. Moreover, compared to olig2 and sox1047–50, Zfp488 is exclusively expressed 
in oligodendrocyte lineage cells33. Here we show that human Zfp488-hNSC also acquire similar fate in vivo in 
response to demyelination/remyelination signals.
One of the objectives of this study was to compare the in vitro differentiation fate of Zfp488-hNSC compared to 
naïve hNSC. As expected, hNSC whether naive or transduced with empty vector, primarily generated beta-tubulin 
positive immature neuron, followed by S100beta and GFAP expressing astrocytes, but rarely oligodendrocytes. 
Thus, this condition was ideal as a suitable baseline for assessing the potential pro-oligodendrogliogenic effects 
of Zfp488. We found that Zfp488 expression inhibited neuronal fate completely while generating OPCs, clearly 
with an oligodendrocyte bias as seen by significantly higher O4-positive oligodendrocytes. Furthermore, pre-OLs 
emerging from Zfp488-hNSC cultures showed a mature phenotype with highly branched processes and forma-
tion of membrane sheet extensions. Overall, our data support the view that Zfp488 expression efficiently directs 
the fate of NSC towards oligodendrocyte fate.
Our second objective was to compare the in vivo differentiation phenotypes of Zfp488-ZsGreen1-hNSCs with 
control hNSCs. The four-week time point was chosen since numerous previous studies have reported that hESC 
derived NSCs remained mostly undifferentiated when transplanted in demyelination models when detected 
after 3–4 weeks30,51. We demonstrated the ability of Zfp488-ZsGreen1-hNSCs to respond appropriately to the 
remyelinating cues in vivo, which include migrating towards the LPC lesion, and differentiate into OPC in a 
demyelinating-remyelinating environment. Although there are many approaches for testing these qualities, we 
used LPC induced demyelination model to assess their fate in a system favoring NSC differentiation without any 
significant inflammation. Following transplantation, the control hNSCs migrated to the lesion area, where they 
differentiated predominantly into GFAP expressing astrocytes, while rest of the cells remained nestin-positive 
undifferentiated cells. Similar to other reports, we failed to detect any transplanted control hNSC derived OPC 
Figure 8. Zfp488-NSCs derived from iPSCs, differentiated into functional oligodendrocytes that generated 
multilayer myelin sheath in Shiverer mice. (A) ZsGreen1 expressing cells co-expressed A2B5 (A1,A2 are 
individual channels). (B) ZsGreen1 cells co-expressed O4 (B1,B2 are individual channels). (C) ZsGreen1 cells 
co-expressed O4 (C1,C2 are individual channels). (D) The percentages of ZsGreen1 cells that were positive for 
A2B5 were 80.5 ± 2.7 (A), for O4 64.8 ± 2.8 (B), and for O1 55.8 ± 2.9 (D). (E) Zfp488-NSC derived O4+ OPCs 
were transplanted in the corpus callosum of adult shiverer mice. Under the electron microscope, multilayered 
myelin sheaths were visible around axons (E,E1). (F) Corpus callosum of control untransplanted Shiverer 
mouse lacked multilayered compact myelin sheath at a similar age (F). The bar is 500 nM.
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or mature oligodendrocytes confirming the low oligodendroglial differentiation efficiency of human NSCs com-
pared with their rodent counterparts52. In contrast, Zfp488 positive cells expressed the OPC marker PDGFRα, 
and astrocyte marker GFAP. Neuronal differentiation was not detected in our system for any group, primarily 
since the corpus callosum is a white matter tract (nonneuronogenic area). Additionally, Zfp488 hNSCs differen-
tiated into late OPC marker O4 expressing OLs and mature premyelinating OLs expressing MBP, O1, and GALC. 
We identified ZsGreen1 (Zfp488) positive tract parallel track in the corpus callosum which colocalized with MBP 
and neurofilament staining displaying evidence of initiation of myelinating by transplanting cells. Thus, misex-
pression of Zfp488 resulted in efficient differentiation of OPC into mature OL than naïve OPCs. We also detected 
human nestin-positive NSCs in the SVZ area indicating that the Zfp488-NSCs were capable of migrating to the 
niche area.
To evaluate the myelination capacity of the OPCs derived from Zfp488-NSCs, we injected them into the cor-
pus callosum of the shiverer mouse brain. The Zfp488 hNSCs could differentiate in vivo in the myelin-deficient 
shiverer mice and successfully generated myelin sheath around the naked axons. In addition, the myelinating 
capacity of iPSC derived Zfp488-NSCs was demonstrated in rat DRG–OPC co-culture. These data indicate that 
direct misexpression of Zfp488 can be used to produce lineage-restricted hNSCs with a high capacity for OPC 
generation and finally functional oligodendrocytes.
The effects of Zfp488 misexpression in this study could be due to a general shift in lineage differentiation 
and an acceleration of oligodendrocyte maturation. Recently, by combining chromatin immunoprecipitation 
sequencing (ChIP-seq) and RNA sequencing (RNA-seq) data, Znf488 (the human ortholog of mouse Zfp488) 
was identified as a critical patterning transcription factor in the ventral spinal cord involved in defining the P1 
and P2 domain progenitor identity in the chicken53. It was shown that Znf488 was expressed together with olig2 
in the P2/pre-motor neuron (pMN) domain at stage HH14 of the chicken neural tube. The pMN domain gives 
rise to OPCs following motor neuron generation. It is possible that mouse ZFP488 may also serve as a pattern-
ing regulator and a morphogen capable of changing the lineage of progenitors towards an oligodendroglial fate. 
Overall, it could be speculated that a novel role of Zfp488 as a neural progenitor patterning factor may explain 
why a TF required for OPC formation and maturation can regulate the fate of NSCs towards oligodendrocytes.
An alternate mechanism for the robust oligodendrocyte fate of the Zfp488-NSCs could be as associated main-
tenance of sox9 expression. The transcription factor Sox9 strongly influences the multipotential neural stem cells 
toward an OPC fate54. Oligodendrocyte specification via SOXE expressions in the CNS is temporally orchestrated 
starting with sox9 expression in the spinal cord neuroepithelium, persisting in OPCs and maintained in adult 
astrocytes54, followed by Sox8 and then sox10 expression. As presented in Supplementary Fig. 6, sox9 mRNA 
levels were reduced when control NSCs were differentiated for 3 days in OPC media, whereas the levels remained 
unchanged in Zfp488-NSCs under the same differentiating conditions. Sox9 mRNA levels were similar between 
undifferentiated Zfp488-NSC and control-NSCs since Zfp488 expression was not switched on before differen-
tiation (discussed in the introduction). Similarly, after transplantation of the control and Zfp488-NSCs in the 
LPC mice model, we detected a significantly higher percentage of ZsGreen1 cells that were Sox9 positive in 
the Zfp488 group, compared to control ZsGreen1 cells, indicating maintenance of sox9 expression in Zfp488 
expressing cells (Supplementary Fig. 6). It has been reported that knocking out Sox9 results in reduced oligoden-
drocytes and increased numbers of motor neurons generated by neural progenitors in the ventral spinal cords 
of mice45. Additional studies show that neurospheres infected with sox9 or sox10 under OL differentiating con-
ditions show a significant increase in OPC generation, demonstrating that that SOX9 and SOX10 enhance OPC 
specification and maturation55. Sox9 is however expressed earlier than sox10 during development. The effect on 
Sox9 on Zfp488 mediate OPC fate restriction could be either direct or indirect. Overall, our protocol used for 
neural differentiation of human ES/iPSC derived neural stem cells, allows for large scale production of uniform, 
Zfp488-ZsGreen1-hNSCs with a predominant oligodendroglial lineage differentiation potential.
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